Metabolic syndrome status numerically affected the median Psoriasis Area and Severity Index score changes in patients receiving Ilumya 100 mg or 200 mg or Enbrel but was not clinically lower, according to research presented at the Academy of Managed Care Pharmacy Nexus.
The retrospective analysis utilized data through week 28 from the reSURFACE 1 and reSURFACE 2 studies in adults with moderate to severe chronic plague psoriasis.
In week 1 to week 12, patients were randomly assigned to placebo, Ilumya (tildrakizumab, Sun Pharma) 100 mg or 200 mg at 1:2:2 at weeks 0 and 4. In reSURFACE 2, an additional arm of Enbrel (etanercept, Amgen) 50 mg was administered twice weekly,
From week 12 to week 28, patients receiving tildrakizumab continued treatment every 12 weeks. Patients assigned placebo were re-randomly assigned to tildrakizumab 100 mg or 200 mg and treated at weeks 12 and 16, according to the study poster. In reSURFACE 2, those on etanercept received 50 mg once weekly.
A total of 137 patients (23.1%) had metabolic syndrome out of 594 patients who continuously received tildrakizumab 100 mg. A total of 123 patients (20.6%) had metabolic syndrome out of 597 patients on tildrakizumab 200 mg and 61 (21.1%) had metabolic syndrome from 289 patients on etanercept.
Similar percentages of patients on tildrakizumab 100 mg regardless of metabolic syndrome status achieved Psoriasis Area and Severity Index (PASI) 100. Fewer patients met PASI 100 in those with metabolic syndrome assigned tildrakizumab 200 mg or etanercept vs. those without, according to the study poster.
At week 28, the change in median PASI did not differ by metabolic syndrome status in those receiving tildrakizumab at either dose or etanercept.
Differences in those achieving PASI 75 and PASI 90 responses based on metabolic syndrome status were limited, according to the poster. Researchers found higher response rates for tildrakizumab 100 mg or 200 mg vs. etanercept.
Additionally, PASI score improvement continued after week 12 for patients regardless of metabolic syndrome status in both tildrakizumab doses, but not in those receiving etanercept. – by Abigail Sutton
Gottlieb AB, et al. Effect of metabolic syndrome on efficacy and safety in patients with psoriasis treated with etanercept or tildrakizumab: Post hoc analysis of 2 phase 3 clinical studies (reSURFACE 1 and reSURFACE 2). Presented at: Academy of Managed Care Pharmacy Nexus; Oct. 29-Nov. 1, 2019; National Harbor, Maryland.
Disclosure: Healio Dermatology could not confirm relevant financial disclosures at the time of publication.